Atara Biotherapeutics Management
Management criteria checks 2/4
Atara Biotherapeutics' CEO is Cokey Nguyen, appointed in Sep 2024, has a tenure of less than a year. total yearly compensation is $1.57M, comprised of 37.2% salary and 62.8% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $218.34K. The average tenure of the management team and the board of directors is 0.5 years and 4.5 years respectively.
Key information
Cokey Nguyen
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 37.22% |
| CEO tenure | less than a year |
| CEO ownership | 0.4% |
| Management average tenure | less than a year |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth
May 06
Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?
May 01Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop
Mar 07Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Jan 21Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jan 16Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?
Jan 07Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Nov 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Sep 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Jul 21Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Jul 03New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$16m |
| Dec 31 2024 | US$2m | US$586k | -US$85m |
| Sep 30 2024 | n/a | n/a | -US$133m |
| Jun 30 2024 | n/a | n/a | -US$181m |
| Mar 31 2024 | n/a | n/a | -US$233m |
| Dec 31 2023 | US$2m | US$540k | -US$276m |
Compensation vs Market: Cokey's total compensation ($USD1.57M) is above average for companies of similar size in the US market ($USD647.92K).
Compensation vs Earnings: Cokey's compensation has been consistent with company performance over the past year.
CEO
Cokey Nguyen (52 yo)
Dr. Anhco Nguyen, Ph D., also known as Cokey, has been the President, Chief Executive Officer and Director of Atara Biotherapeutics Inc. since September 09, 2024. He served as Chief Scientific Officer at A...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$1.57m | 0.40% $ 218.3k | |
| Chief Accounting Officer & Principal Accounting Officer | less than a year | no data | 0.13% $ 73.7k | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Head of Legal | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data |
Experienced Management: ATRA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$1.57m | 0.40% $ 218.3k | |
| Director | less than a year | no data | no data | |
| Independent Director | 9.7yrs | US$170.76k | 0.24% $ 132.5k | |
| Independent Director | 11.3yrs | US$169.10k | 0.17% $ 95.6k | |
| Lead Independent Director | 12.5yrs | US$191.55k | 0.42% $ 232.4k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.9yrs | US$166.60k | 0.15% $ 84.0k | |
| Independent Director | 5.2yrs | US$159.10k | 0.16% $ 88.1k | |
| Chairman of the Board | 6.1yrs | US$1.95m | 0.64% $ 354.4k | |
| Director | less than a year | no data | no data |
Experienced Board: ATRA's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 21:14 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atara Biotherapeutics, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Yigal Nochomovitz | Citigroup Inc |
| Michael King | Citizens JMP Securities, LLC |